

SCN 2018-19 Funding Results: Clinical Trials

Principal Investigator	Co-Investigator	Project Title	SCN Funds Allocated
Jean Roy – Hôpital Maisonneuve- Rosemont (HMR)	Guy Sauvageau (UdeM), Jean-Sebastien Delisle (HMR), Richard Leblanc (HMR), Sandra Cohen (HMR), Silvy Lachance (HMR), Imran Ahmad (HMR), Émilie Lemieux-Blanchard (CRCHUM), Michael Sebag (MUHC), Sebastien Lemieux (UdeM), Gabriel Tremblay (Geneconomic)	Allogeneic stem cell transplant using UM171 expanded cord bloods for patients with high-risk multiple myeloma	\$500,000
James Shapiro – U of A	Peter Senior (U of A), Peter Light (U of A), Gregory Korbitt (U of A), Eugene Brandon (Viacyte Inc.), Kevin D'Amour (Viacyte Inc.), Howard Foyt (Viacyte Inc.), Sylvain Bedard (CEPPP), Bart Roep (U Leiden), Joanna Preston (TEC Edmonton), Chris McCabe (U of A)	Pancreatic Progenitor Cell Therapy: Solving Supply and Survival Issues of Islet Cell Transplantation for T1DM	\$500,000
Duncan Stewart – OHRI	David Courtman (GMP Facility OHRI), Michael Kutryk (SMH), Chris Glover (UOHI), Hung-Ly Quoc (MHI), Alexander Dick (UOHI), Michel Lemay (UOHI), Kim Connelly (SMH), Howard Leong Poi (SMH), Josep Rodes-Cabau (U Laval), Dominique Joyal (JGH)	Enhanced Angiogenic Cell Therapy for Acute Myocardial Infarction (ENACT-AMI)	\$500,000

* Project titles posted as per the language of submission

Clinical Trials Summary

Applications Received	Applications Recommended for Funding	Percentage of Successful Applications	Total Investment
4	3	75%	\$1.5 million

SCN 2018-19 Funding Results: Disease Team Program

Principal Investigator	Co-Investigator	Project Title	SCN Funds Allocated
Gilbert Bernier – Hôpital Maisonneuve-Rosemont (HMR)	May Griffith (UdeM), Jean-Francois Bouchard (UdeM), Flavio Rezende (HMR), Cynthia Qian (UdeM), Mario Filion (INRS)	Macula transplantation for the treatment of retinal degenerative diseases	\$200,000
Joanna Matsubara – UBC	Marinko Sarunic (SFU), David Maberly (UBC), Orson Moritz (UBC), Arif Samad (DU), Sean Lumb (UBC)	Treating advanced retinal degeneration – rebuilding multiple co-dependent retinal layers with stem cells	\$100,000
Lauralyn McIntyre – OHRI	Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (Hamilton Health Sciences Corporation), Margaret Herridge (UHN), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI), Dana Devine (CBS)	Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial	\$200,000
Freda Miller – The Hospital for Sick Children	Donald Mabbott (HSC), David Kaplan (HSC), Cindi Morshead (U of T), Jing Wang (OHRI),	Pharmacological recruitment of endogenous neural precursors to	\$200,000

(HSC)	Ann Yeh (HSC), Douglas Munoz (Queens U), Paul Frankland (HSC), Wolfram Tetzlaff (UBC), Brian Nieman (HSC)	promote pediatric white matter repair	
Massimiliano Paganelli – CHU Sainte-Justine, UdeM	Elie Haddad (UdeM), Christian Beausejour (UdeM), Ariella Shikanov (U of Michigan), Serge McGraw (UdeM), Yves Théoret (CHU Sainte-Justine), Michel Lallier (CHU Sainte-Justine)	Safety and efficacy of stem cell-derived encapsulated liver tissue to treat liver failure without immunosuppression	\$100,000
James Shapiro – U of A	Gregory Korbitt (U of A), ViaCyte Inc., Joanna Preston (TEC Edmonton), Peter Senior (U of A), Bruce Verchere (UBC)	Development of a novel stem cell-derived transplant modality for type 1 diabetes	\$100,000
Bruce Verchere – UBC	Francis Lynn (UBC), Megan Levings (UBC), Tim Kieffer (UBC), Dina Panagiotopoulos (UBC), Brad Hoffman (UBC), Garth Warnock (UBC), Gregory Korbitt (UofA)	Genetic manipulation of hES-derived insulin-producing cells to improve graft outcomes	\$200,000

* Project titles posted as per the language of submission

Disease Team Program Summary

Applications Received	Applications Recommended for Funding	Percentage of Successful Applications	Total Investment
11	7	64%	\$1.1 million

SCN 2018-19 Funding Results: Impact Research Program

Investigators	Project Stream	Project Title	SCN Funds Allocated
<p>Florian Bentzinger – UdeSherbrooke (Principal Investigator)</p> <p>Eric Marsault (UdeSherbrooke), Mannix Auger-Messier (UdeSherbrooke), Nicolas Dumont (CHU-Sainte-Justine, UdeM), Frederic Balg (UdeSherbrooke)</p>	Discovery Translation	Apelinergic Compounds for the treatment of muscular dystrophy	\$99,000
<p>Mick Bhatia – McMaster (Principal Investigator)</p> <p>Rima Al-Awar (OICR)</p>	Discovery Translation	Identification of kinases and their target substrates in early human PSC specification	\$100,000
<p>Timothy Caulfield – U of A (Principal Investigator)</p> <p>Amy Zarzeczny (UofR), Barbara von Tigerstrom (UofA), Tania Bubela (SFU), Yann Joly (McGill), Zubin Master (Mayo Clinic), Jeremy Snyder (SFU), Ubaka Ogbogu (UofA)</p>	Public Policy	The Next Step: Specific Strategies for Addressing the Marketing of Unproven Stem Cell Therapies	\$40,000
<p>Nicolas Dumont – CHU Sainte-Justine, UdeM (Principal Investigator)</p> <p>Sylvie Girard (UdeM), Cam-Tu Nguyen</p>	Discovery Translation	Targeting muscle stem cells to mitigate Duchenne muscular dystrophy	\$100,000

(UdeM), Phillipe Campeau (UdeM), Christian Beauséjour (UdeM)			
John Hassell – McMaster (Principal Investigator)	Discovery Translation	HTR5A as a target for anticancer stem cell drug discovery	\$99,500
Rima Al-awar (OICR)			
Timothy Kieffer – UBC (Principal Investigator)	Clinical Translation & Accelerator	Assessment of Cell Maturation and Function in Subcutaneous Macroencapsulation Devices in Rodents	\$100,000
Ali Rezania (Viacyte Inc.)			
Bartha Knoppers – McGill (Principal Investigator)	Public Policy	Reforming Canadian Stem Cell Policy: Moving Beyond the Assisted Human Reproduction Act (AHRA)	\$39,736
Rosario Isai (OHRI), Tim Caulfield (UofA), Amy Zarzeczny (UofR), Tania Bubela (SFU), Ubaka Ogbogu (UofA), Vardit Ravitsky (UdeM)			
Zachary Laksman – UBC (Principal Investigator)	Clinical Translation & Accelerator	Using stem cells to test new drugs for atrial fibrillation	\$100,000
Glen Tibbits (SFU)			
Lauralyn McIntyre – OHRI (Principal Investigator)	Clinical Translation & Accelerator	Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial	\$100,000
Shirley Mei (OHRI), Duncan Stewart (OHRI),			

Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (McMaster), Margaret Herridge (U of T), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI)			
Derrick Rancourt – UC (Principal Investigator)	Commercialization	Enhancing the Efficiency of Genome Engineering in Human Pluripotent Stem Cells	\$100,000
Eric Jervis (STEMCELL Technologies)			
Bernard Thébaud – OHRI (Principal Investigator)	Clinical Translation & Accelerator	Endothelial Progenitor Cell-derived Therapies for Neonatal Pulmonary Hypertension	\$99,905
Mervin Yoder (Hospital for Children, Indianapolis), Dylan Burger (U of O)			
Glen Tibbits – SFU (Principal Investigator)	Clinical Translation & Accelerator	Developing an hiPSC-CM based protocol to investigate SIDS-implicated sudden cardiac arrest in infants	\$99,500
Thomas Claydon (SFU), Zachary Laksman (UBC), Shubhayan Sanatani (UBC)			
Eve Tsai – OHRI (Principal Investigator)	Clinical Translation & Accelerator	Translating an animal endogenous stem/progenitor cell repair strategy for	\$100,000

Xudong Cao (U of O), Ruth Slack (U of O)		stroke to humans	
Peter Zandstra – UBC (Principal Investigator)	Commercialization	A robust, quantitative, and high-throughput assay to rapidly characterize human induced pluripotent stem cells	\$100,000
Fiona Watt (King’s College, London, UK), Davide Danovi (King’s College, London, UK)			

* Project titles posted as per the language of submission

Impact Research Program Summary

Applications Received	Applications Recommended for Funding	Percentage of Successful Applications	Total Investment
46	14	30%	\$1.4 million